News, events, and resources
Feb 16, 2026
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Biosolutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis, and development strategy.
Feb 16, 2026
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
Feb 4, 2026
The 6 Most Common Analytical Gaps in Biosimilar Programs (and how to fix them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
Feb 3, 2026
WCBP 2026: Why Comparability is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
Jan 12, 2026
New Head of West Coast business development at CBS, Allan Cortes!
Allan Cortes joins CBS as Head of West Coast business development, bringing unparalleled experience in biotech and CRO business development.
Dec 22, 2025
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solution is attending as exhibitor at WCBP 2026. What is WCBP, who should attend, and why it matters for CMC and biologics.
Dec 15, 2025
Sterility Assays in Drug and Device Manufacturing
Sterility and endotoxin assays are essential GMP tests ensuring drug and device safety, regulatory compliance, and reliable release across ...
Dec 15, 2025
Critical Quality Attribute D0 Impact in ADC Modality
Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.
Dec 15, 2025
Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality
Overview of ADC components and related CQAs, highlighting how antibody, linker, and payload heterogeneity affect potency, stability and ...
Nov 21, 2025
Strategies for Antibody-Drug Conjugates Bioanalysis
Antibody-drug conjugates (ADCs) bioanalysis requires robust methods to track antibodies, payloads, and drug-to-antibody ratio changes in ...
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Biosolutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis, and development strategy.
WCBP 2026: Why Comparability is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
New Head of West Coast business development at CBS, Allan Cortes!
Allan Cortes joins CBS as Head of West Coast business development, bringing unparalleled experience in biotech and CRO business development.
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solution is attending as exhibitor at WCBP 2026. What is WCBP, who should attend, and why it matters for CMC and biologics.
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
The 6 Most Common Analytical Gaps in Biosimilar Programs (and how to fix them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
Strategies for Antibody-Drug Conjugates Bioanalysis
Antibody-drug conjugates (ADCs) bioanalysis requires robust methods to track antibodies, payloads, and drug-to-antibody ratio changes in ...
Sterility Assays in Drug and Device Manufacturing
Sterility and endotoxin assays are essential GMP tests ensuring drug and device safety, regulatory compliance, and reliable release across ...
Critical Quality Attribute D0 Impact in ADC Modality
Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.
Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality
Overview of ADC components and related CQAs, highlighting how antibody, linker, and payload heterogeneity affect potency, stability and ...
